Why is colorectal cancer well-suited for screening?
Colorectal cancer is the fourth most common cancer affecting Canadians, and the second most common cause of cancer-related death. It occurs roughly equally in men and women, and the lifetime probability of developing colorectal cancer is estimated to be 6%, of which about half will die of the disease. 1 Colorectal cancer is particularly well-suited for screening because: 1. There is a good understanding of the sequence whereby an adenomatous polyp evolves into cancer. 2. There is a long latency period between the development of a polyp and invasive cancer. 3. There are a number of acceptable and safe screening tests. 4 . Advancements in endoscopic interventions allow us not only to diagnose early, but also to prevent cancer. 5. There are well-known risk groups on whom screening can be focused.
What are the risks?
There are three risk categories for colorectal cancer (Table 1 ).
John's case
John, 48, has had no significant medical illnesses. He presents complaining of pruritus. During his visit, he mentions that one of his 55-year-old colleagues was recently diagnosed with colon cancer. He requests to be screened to reassure himself and his family, but denies having any symptoms.
• FOBT FOBT is the least invasive way to screen for colorectal cancer. It involves the testing of two samples from three consecutive stools for occult blood. Patients must abstain from red meat, certain vegetables and fruits (melons, radishes, turnips, beets, horseradish), vitamin Dr. Rosen is a colon and rectal surgeon, Calgary, Alberta. C, and non-steroidal anti-inflammatory drugs for at least 72 hours prior to the test. The accuracy of FOBT may also be compromised by the presence of anorectal disorders, such as hemorrhoids or fissures. Three randomized, prospective studies have demonstrated a 15% to 33% decrease in colorectal cancer-related deaths when FOBT is used properly. [3] [4] [5] In the Minnesota study, 46,551 people were followed over 13 years. It was concluded that 339 people needed to be screened annually for 13 years to prevent one death from colorectal cancer. 3 FOBT is the recommended test of the Canadian Cancer Society. FS FS directly visualizes the rectum and sigmoid colon. There are several case-controlled studies which demonstrate approximately a 50% decrease in colorectal cancer mortality from cancer within the reach of the sigmoidoscope. 6, 7 Until recently, it was believed that although FS only visualizes the distal onethird of the colon, most significant lesions were within its reach. This belief has been shattered with the publication of two studies which suggest that up to 50% of people with significant proximal lesions will not have anything of significance within the reach of the sigmoidoscope. 8, 9 A followup on John Because John is an average-risk individual, it is reasonable to screen him.
The Canadian Cancer Society recommends fecal occult blood testing, but I would offer him a flexible sigmoidoscopy and air contrast barium enema. If he specifically requested colonoscopy, I would agree to do it after explaining to him the risks, benefits, and alternatives.
According to the data we have at present, the fact that his father died at 82 from colorectal cancer would not change John's risk category, though, in reality, it would incline most specialists to consider colonoscopy first. 
Take-home message
Computed tomography (CT) colonography allows for a three-dimensional reconstruction of the colon. Because it is expensive, requires a full bowel preparation, and still has significant false positives, I think it is unlikely that it will replace the other tests. Some other possible screening tests, including capsule video endoscopy and stool tests for DNA mutations/molecular markers, show promise, but are still experimental. Because of its excellent accuracy and therapeutic potential, colonoscopy will likely remain the gold standard for many years to come.
Who should be screened, and how?
The question family physicians must address is how to screen their patients for colorectal cancer. Increased-risk and high-risk patients need to be referred to a specialist for colonoscopy. Average-risk patients, however, remain a conundrum.
We are faced with the dilemma of a relatively cheap, safe, mediocre test (FOBT) versus an expensive, slightly risky, excellent test (colonoscopy). One of the problems with all other screening tests is that if any of them are positive, a colonoscopy is still the next step to confirm diagnosis and clear the remainder of the colon. Therefore, there is a tendency to try to cut out the middle steps and use colonoscopy directly, but this would be enormously expensive.
Screening for colorectal cancer raises many challenging public policy questions about how we wish to distribute our limited resources.
